anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide the coloring agent excellent in warm temperature resistance and capable of stably producing a color. CONSTITUTION:The coloring agent contains >=50wt.% of a maltitol difatty acid ester, e.g. maltitol diisostearate ester, purified by the solvent fractionation of maltitol fatty acid esters and an anionic or cationic surfactant, especially preferably a 12-22C fatty acid soap containing Na, K or triethanolamine as the counter ion, in an amount of >=0.5%. The further addition of an amphipathic substance, preferably a higher fatty acid or higher fatty alcohol in an amount of >=0.1%, gives the stable and brilliant color-producing coloring agent. When homogeneously dispersed in an amount of 1.0-3.5wt.% in water and controlled to <= the Tc (the solid-liquid transition temperature of the diester in a solution) of the diester, the coloring agent gives a coloring composition releasing a brilliant lustrous color. A dispersion containing the coloring agent in a low content gives a dispersion having a long wavelength color, and a dispersion containing the coloring agent in a high content gives a dispersion having a short wave length color.
Both spironolactone and finerenone treatments significantly reduced SBP and there was no statistical difference in their antihypertensive effects. The differences in body weight (at the end of 1/2/3/4 week) to pre-dose body weight ratio and heart rate (at the end of 1/2/3/4 week) to pre-dose heart rate ratio were not statistically significant in the vehicle, spironolactone, finerenone, and control groups.There was no statistically significant difference in mortality among the vehicle, spironolactone, and finerenone groups. The relative heart mass, ANP, BNP, CVF, Col I, TGF-β, and Casp-3 were gradually decreased in vehicle group, spironolactone group, and finerenone group. Among them, BNP, CVF, TGF-β, and Casp-3 were significantly decreased in the finerenone group compared with the vehicle group. HE and Masson staining showed that the cardiomyocytes of rats in the vehicle group and spironolactone group were disorganized, with cell hypertrophy, significantly enlarged cell gaps and a large amount of collagen deposition, whereas the cardiomyocytes of rats in the finerenone group and the control group were more neatly arranged, with smaller cell gaps and a small amount of collagen tissue deposition. RNA sequencing (RNA-seq) showed that there was a total of 119 differentially expressed genes (DEGs) between finerenone treatment and vehicle treatment. Kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis showed that the signaling pathways involved were mainly in drug metabolism-cytochrome P450, chemical carcinogenesis, IL-17 signaling pathway, axon guidance, and hematopoietic cell lineage. Protein-protein interaction (PPI) analysis showed that the core genes were Oaslf, Nos2, LOC687780, Rhobtb1, Ephb3, and Rps27a.
An apparatus for automatically mapping a verbatim narrative to a term in a medical terminology dictionary includes a natural language processor and a comparator. The natural language processor processes terms from the medical terminology dictionary and from a medical coding decision database to generate a processed database that also includes the original terms from the medical terminology dictionary and the medical coding decision database. The natural language processor also processes the verbatim narrative. The comparator compares the processed verbatim narrative to the terms in the processed database and determines whether the processed verbatim narrative is an exact match to a term in the processed database. The verbatim narrative is mapped to the term in the medical terminology dictionary that corresponds to the term in the processed database that is an exact match. The verbatim narratives may include adverse event narratives, concomitant medication narratives, or other types of narratives. A method for automatically mapping a verbatim narrative to a term in a medical terminology dictionary is also described and claimed.
INTRODUCTION: Despite technological developments and intensified care, pregnancies in women with pre-existing diabetes are still considered high-risk pregnancies. The rate of adverse outcomes in pregnancies affected by diabetes in Denmark is currently unknown, and there is a limited understanding of mechanisms contributing to this elevated risk. To address these gaps, the Danish Diabetes Birth Registry 2 (DDBR2) was established. The aims of this registry are to evaluate maternal and fetal-neonatal outcomes based on 5 years cohort data, and to identify pathophysiology and risk factors associated with short-term and long-term outcomes of pregnancies in women with pre-existing diabetes.
METHODS AND ANALYSIS: The DDBR2 registry is a nationwide 5-year prospective cohort with an inclusion period from February 2023 to February 2028 of pregnancies in women with all types of pre-existing diabetes and includes registry, clinical and questionnaire data and biological samples of mother-partner-child trios. Eligible families (parents age ≥18 years and sufficient proficiency in Danish or English) can participate by either (1) basic level data obtained from medical records (mother and child) and questionnaires (partner) or (2) basic level data and additional data which includes questionnaires (mother and partner) and blood samples (all). The primary maternal outcome is Hemoglobin A1c (HbA1c) levels at the end of pregnancy and the primary offspring endpoint is the birth weight SD score. The DDBR2 registry will be complemented by genetic, epigenetic and metabolomic data as well as a biobank for future research, and the cohort will be followed through data from national databases to illuminate possible mechanisms that link maternal diabetes and other parental factors to a possible increased risk of adverse long-term child outcomes.
ETHICS AND DISSEMINATION: Approval from the Ethical Committee is obtained (S-20220039). Findings will be sought published in international scientific journals and shared among the participating hospitals and policymakers.
TRIAL REGISTRATION NUMBER: NCT05678543.
Allograft particles should be hydrated with GEM21S for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane.
The invention discloses a targeting hydroxycamptothecin bean phospholipid nano freeze-dried powder injection preparation. The composite material is prepared from the following main raw materials in percentage by weight: 1-5 parts of active raw material hydroxycamptothecin, 1-10 parts of carrier soybean lecithin, 2-20 parts of freeze-drying auxiliary materials and surfactant poloxamer or tween-80 or span-651. Putting hydroxycamptothecin and soybean phospholipid into a container, adding an organic solvent, and heating in a water bath for dissolving; then evaporating under reduced pressure to remove the solvent; adding a surfactant under the condition of introducing nitrogen, and stirring at a high speed; and (4) carrying out ultrasonic treatment on the stirred solution, adding a mannitol aqueous solution, and carrying out freeze-drying on the finished product. The nano powder injection has excellent targeting property, and has medicine concentration in the tissues of main organs obviously higher than that of common powder injection, wherein the medicine concentration in the liver is 37.66 times (15 minutes), 23.04 times (60 minutes) and 14.65 times (120 minutes) of that of common powder injection. The nano powder injection has obvious accumulated target tissues or organs. The preparation method is simple and easy to realize, and the encapsulation rate of the medicine can reach 98.73 percent.
The invention discloses a compound preparation containing red yeast rice, and belongs to the technical field of medical and healthcare products. The provided compound preparation is composed of the following raw materials in parts by weight: 100 to 200 parts of red yeast rice, 50 to 100 parts of natto, and 250 to 350 parts of perilla oil. The red yeast rice, natto, and perilla oil are evenly mixed according to the ratio mentioned above so as to obtain the compound preparation. The compound preparation can be made into soft capsules, particles, tablets, or oral liquid according to the actual needs. The provided compound preparation has the functions of dissolving thrombus, controlling blood fat, and reducing blood pressure, and at the same time has the advantages of safety, reliability, and no side or toxic effect. The perilla oil and natto are mixed to protect natto kinase from gastric acid so as to guarantee the activity of natto kinase.
Orphenadrine Citrate Injection is a sterile aqueous solution of orphenadrine citrate. It is intended for intravenous or intramuscular administration.

Orphenadrine citrate is the citrate salt of orphenadrine and occurs as a white, crystalline powder having a bitter taste. It is practically odorless, sparingly soluble in water and slightly soluble in alcohol. It has the following structural formula:

N,N-Dimethyl-2-[(o-methyl-α-phenylbenzyl)oxy]ethylamine Citrate (1:1).

Each mL contains: Orphenadrine Citrate 30 mg, Sodium Metabisulfite 0.91 mg, Sodium Chloride 2.9 mg, in Water for Injection q.s. Sodium Hydroxide and/or Hydrochloric Acid may have been used to adjust pH.
The present invention generally describes particles, including nanocapsules or other nanoentities, which comprise polysialic acid to act as transporters of drugs or other active substances into cells, or other applications. In one aspect, the invention relates to nanocapsules or other entities having an exterior, a cover or a surface comprising polysialic acid. In some cases, the binding of targeting groups such as tLyp-1 to polysialic acid is described, for example, using aminoalkyl (C1 -C4) succinimide or other spacers . The targeting groups may be linked to the polysialic acid, for example, by a reaction of the carboxylate group of a polysialic acid with an N-hydroxysuccinimide or a carbodiimide, and by reacting the formed intermediate with a lysine or arginine group of a targeting peptide to produce polysialic acid-amide-peptide. Other aspects of the invention are generally directed to methods for making or using compositions, kits including such compositions, or the like. (Machine-translation by Google Translate, not legally binding)
PURPOSE: To explore the predictive value of radiomics in predicting stroke-associated pneumonia (SAP) in acute ischemic stroke (AIS) patients and construct a prediction model based on clinical features and DWI-MRI radiomics features.
METHODS: Univariate and multivariate logistic regression analyses were used to identify the independent clinical predictors for SAP. Pearson correlation analysis and the least absolute shrinkage and selection operator with ten-fold cross-validation were used to calculate the radiomics score for each feature and identify the predictive radiomics features for SAP. Multivariate logistic regression was used to combine the predictive radiomics features with the independent clinical predictors. The prediction performance of the SAP models was evaluated using receiver operating characteristics (ROC), calibration curves, decision curve analysis, and subgroup analyses.
RESULTS: Triglycerides, the neutrophil-to-lymphocyte ratio, dysphagia, the National Institutes of Health Stroke Scale (NIHSS) score, and internal carotid artery stenosis were identified as clinically independent risk factors for SAP. The radiomics scores in patients with SAP were generally higher than in patients without SAP (P < 0. 05). There was a linear positive correlation between radiomics scores and NIHSS scores, as well as between radiomics scores and infarct volume. Infarct volume showed moderate performance in predicting the occurrence of SAP, with an AUC of 0.635. When compared with the other models, the combined prediction model achieved the best area under the ROC (AUC) in both training (AUC = 0.859, 95% CI 0.759-0.936) and validation (AUC = 0.830, 95% CI 0.758-0.896) cohorts (P < 0.05). The calibration curves and decision curve analysis further confirmed the clinical value of the nomogram. Subgroup analysis showed that this nomogram had potential generalization ability.
CONCLUSION: The addition of the radiomics features to the clinical model improved the prediction of SAP in AIS patients, which verified its feasibility.
The invention discloses a cheese bacillus strain WFP1-1, a composite bacterial agent and application thereof, and belongs to the technical field of microorganisms. The class of Lactobacillus paracasei WFP1-1 was designated Lacticaseibacillus paracesei and deposited with the microorganism strain collection, guangzhou province, under the accession number GDMCCNo.62587. The Lactobacillus paracasei WFP1-1 has good inhibition effect on Streptococcus mutans, fusobacterium nucleatum and Porphyromonas gingivalis. Meanwhile, the invention also provides a composite microbial inoculum containing the cheese bacillus WFP1-1 and the bifidobacterium longum WFP05. Wherein, bifidobacterium longum WFP05 is deposited with the accession number GDMCCNo.62592. The composite microbial inoculum has obvious comprehensive antibacterial effect on oral harmful bacteria, the self-coagulation rate reaches 88.2%, and the co-coagulation rate with streptococcus mutans reaches 86.53%. Animal experiments prove that the viable bacteria or the inactivated form of the composite bacterial agent has the efficacy of preventing dental caries, is beneficial to preventing dental caries, periodontitis and other oral diseases, and has wide application prospect in foods, health care products, medicines or daily chemicals with the efficacy of freshening breath.
A diagnostic station integrates patient support, imaging, biopsy, and treatment. An illustrative version of a prone mammography table localizes a breast with an imaging modality (e.g., X-ray, etc.) based upon a rotating C-arm that may encircle the localized breast. A biopsy system is integrated into the controls and displays or user interface of the diagnostic station, sharing integrated utilities (e.g., vacuum, power, data communication, etc.). Ancillary devices may be identified and authenticated by the integrated system, such as to base available functionality on the identification and/or authentication of an ancillary device. Ancillary devices that may be integrated with the system may include devices that are operable to perform surgical, therapeutic, diagnostic, or other functions.
Severe traumatic brain injuries typically result in loss of consciousness or coma. In deeply comatose patients with traumatic brain injury, cortical dynamics become simple, repetitive, and predictable. We review evidence that this low-complexity, high-predictability state results from a passive cortical state, represented by a stable repetitive attractor, that hinders the flexible formation of neuronal ensembles necessary for conscious experience. Our data and those from other groups support the hypothesis that this cortical passive state is because of the loss of thalamocortical input. We identify the unpredictability and complexity of cortical dynamics captured by local field potential as a sign of recovery from this passive coma attractor. In this Perspective article, we discuss how these electrophysiological biomarkers of the recovery of consciousness could inform the design of closed-loop stimulation paradigms to treat disorders of consciousness.
OBJECTIVES: This population-based cohort study investigated mid-term outcome after surgical aortic valve replacement with a bioprosthetic or mechanical valve prosthesis in patients aged <50 years in a European social welfare state.
METHODS: We analysed patient data from the main social insurance carriers in Austria (2010-2020). Subsequent patient-level record linkage with national health data provided patient characteristics and clinical outcome. Survival, reoperation, myocardial infarction, heart failure, embolic stroke or intracerebral haemorrhage, bleeding other than intracerebral haemorrhage and major adverse cardiac events were evaluated as outcomes.
RESULTS: A total of 991 patients were analysed. Regarding demographics, no major differences between groups were observed. Multivariable Cox regression revealed no significant difference in overall survival (P = 0.352) with a median follow-up time of 6.2 years. Reoperation-free survival was decreased (hazard ratio = 1.560 [95% CI: 1.076-2.262], P = 0.019) and the risk for reoperation was increased (hazard ratio = 2.770 [95% CI: 1.402-5.472], P = 0.003) in patients who received bioprostheses. Estimated probability of death after reoperation was 0.23 (CL: 0.08-0.35) after 2 years and 0.34 (CL: 0.06-0.53) after 10 years over both groups. Regarding further outcomes, no significant differences between the two groups were observed.
CONCLUSIONS: In patients below 50 years of age receiving aortic valve replacement, implantation of bioprostheses when compared to mechanical heart valve prostheses was associated with a significantly higher rate of reoperations and reduced reoperation-free survival. Nevertheless, we could not observe a difference in overall survival. However, long-term follow-up has to evaluate that a significantly lower rate of reoperations may translate in consistently improved long-term survival.
There was no evidence of carcinogenicity in a 113-week oral study in mice at doses up to 40 mg/kg/day (7 times the maximum recommended human dose [MRHD] on a mg/m basis). There was also no evidence of carcinogenicity in rats orally dosed at up to 40 mg/kg/day for 71 weeks followed by 20 mg/kg/day (14 and 7 times the MRHD on a mg/m basis, respectively) through 128 weeks. 22

Memantine produced no evidence of genotoxic potential when evaluated in the or reverse mutation assay, an chromosomal aberration test in human lymphocytes, an cytogenetics assay for chromosome damage in rats, and the mouse micronucleus assay. The results were equivocal in an gene mutation assay using Chinese hamster V79 cells. in vitro S. typhimuriumE. coliin vitroin vivoin vivoin vitro

No impairment of fertility or reproductive performance was seen in rats administered up to 18 mg/kg/day (6 times the MRHD on a mg/m basis) orally from 14 days prior to mating through gestation and lactation in females, or for 60 days prior to mating in males. 2
To define the role of continuation electroconvulsive therapy (C-ECT) in relapse-prevention of seriously ill patients with major depressive disorder (MDD). To determine the relative efficacy and safety of C-ECT in comparison to the traditional approach of continuation pharmacotherapy (C-PHARM) to prevent relapses of MDD.

Electroconvulsive therapy (ECT) is a highly effective treatment for MDD that is helpful for patients with the most severe forms of affective illness; however, relapse after successful acute phase ECT or pharmacotherapy remains a major public health problem. To prevent relapse in patients with MDD who have responded to ECT, the common practice is to prescribe an antidepressant (e.g., a tricyclic \[TCA\], a selective serotonin reuptake inhibitor \[SSRI\], or lithium) as continuation therapy. Recent studies show an alarmingly high relapse rate after ECT despite conventional continuation pharmacotherapy (C-PHARM). Continuation ECT (C-ECT) is also in widespread clinical use; however, its efficacy and safety have never been rigorously tested.

Investigators at four sites (Mayo Clinic, UMDNJ-New Jersey Medical School, Zucker Hillside Hospital, and University of Texas SW Medical Center, Dallas) randomize patients to receive either C-ECT or an aggressive pharmacological strategy (nortriptyline and lithium in combination, \[NOR-Li\]) for 6 months following response to acute phase ECT. Raters at each site evaluate symptoms and side effects. On the basis of edited videotapes obtained at regular intervals, a site-independent, blinded evaluator also assesses symptoms. A neuropsychological battery is administered prior to acute phase ECT, shortly after the ECT course, 3 months after the end of the acute phase treatment, and at the end of the 6-month continuation trial. These continuation therapies are compared in their effects on relapse, cognitive performance, global functioning, side effects, and perceived health status. NOR and Li levels are optimized by blood level monitoring. Bilateral ECT, at progressively increasing intervals, are used for C-ECT. Methods are included to ensure the integrity of clinical diagnoses, symptom severity assessment, data collection and entry, and treatment delivery. In all patients, surreptitious use of prescription or recreational drugs is monitored by urine testing.
PURPOSE:A carcinostatic agent that contains a specific aminopyrazole derivative or its salt as an active ingredient. CONSTITUTION:The objective carcinostatic agent contains 1-phenyl-5-amino- or 4,5-diamino-pyrazole of the formula (R is H, amino) or its salt as an active ingredient. The compound of the formula or its salt inhibits the proliferation of cancer cells, showing good carcinostatic activity. It is orally given in a form of tablets or capsules, injected as a solution or used as a suppository. The dose is 50-2,000mg/adult/day, when it is given orally, and 20-500mg in injection. The LD50 of a compound of the formula where R is H is 700mg/kg. rat and that of a compound where R is amino, is 120mg/kg. rat.
Methods to allow for patient/consumers to collect, store, organize, password protect, and share personal health, medical, dental, and pharmacy data without regard to healthcare provider systems are provided. Application software necessary for complete functionality is contained on a portable, pocket sized, re-write enabled compact disk. Application software necessary for providers (doctors, dentists, hospitals, pharmacies) to view, print, and modify data points is contained on the compact disk. Communication software for the automatic updating of patient information by provider billing/management systems is contained on the compact disk. All software functions necessary for the user/patient and providers to collect, store, update, organize, and share patient information is contained within the application software imbedded on the compact disk. The compact disk therefore is the medium for consumers to collect, organize, store, and share their patient information with providers authorized by the consumer thus optimizing the health history information available to providers. Providing this information to care givers at the time of service serves to improve care and protect the consumer from endangerment due to lack of health history information, care conflicts, and/or drug-drug interactions. Consumer/patient control of access to the application further serves to protect against breech of privacy and confidentiality.